Mentions
Extended reach
Total likes
Video views
AI synopsis
The social discussions demonstrate a strong collective concern about muscle loss during obesity treatment with incretin-mimetic drugs, referencing strategies such as resistance exercise and proper nutrition. Words like 'minimize,' 'maximize,' and 'strategies' reflect proactive attitudes, contributing to a moderate overall engagement and recognition of potential health impacts.
Most discussions support the article's focus on using resistance exercise and nutrition to prevent muscle loss, indicating general agreement.
There is high interest, as many social discussions highlight concerns about muscle loss and strategies to mitigate it, showing engagement with the topic.
Posts reference specific strategies like resistance training and nutritional management, suggesting moderate depth of participation.
The emphasis on the importance of lifestyle management hints at a potential influence on clinical approaches, though it remains somewhat speculative.
Hey! What can we do to avoid lean mass loss with weight loss? Check out this recent paper with me: Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity https://t.co/S81wbAw4E6
The benefits of incretin-memetic drugs (IMD) are clear
肥満治療にGLP-1RAを使う上で筋肉の減少を最大限に減らすための戦略 適切な栄養管理：十分なタンパク質摂取は、筋肉の維持に不可欠 運動の実施：レジスタンストレーニング 個別化された治療計画：患者の状態や目標に合わせた治療計画を立てる https://t.co/RtfsSVIgEQ
Users of incretin-mimetics in obesity trials lost ≥10% of muscle mass during the 68 -72 week interventions, approx equivalent to 20 yrs of age-related muscle loss. Strategies for minimizing muscle loss during use of IMs drugs for treatment of obesity https://t.co/dsMrPXq7WE https://t.co/R2ZEwFSUhb
@DrCarlaPrado @imwmhealth @DrZhaopingLi @heymsfield @DrNadolsky Okay, now go read the full study here: https://t.co/fKGEAJpHa1
Are you losing muscle while using weight loss drugs like Semaglutide and Ozempic? New research shows significant muscle loss with these medications, but there are solutions. Learn critical steps to preserve muscle and…
In today's podcast, we discuss essential strategies for minimizing muscle loss while taking GLP-1 agonist medications. We also explore if exercise is the best treatment for osteoarthritis and the significant impact of…
Review Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity Jeffrey I Mechanick et al. Obes Rev. 2025 Jan. https://t.co/5NxfjJDW5w
Estrategias para minimizar la pérdida muscular durante el uso de medicamentos miméticos de incretina para el tratamiento de la obesidad. Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity - PubMed https://t.co/uS7hogcql1
⬧腸泌素相關藥物（如 Semaglutide 和 Tirzepatide）雖然能有效減重，但可能導致肌肉流失，約相當於 20 年老化造成的流失量。 ⬧維持肌肉的兩大關鍵策略：充足的營養攝取、規律的運動訓練。 https://t.co/UwBv8wRWyE https://t.co/1FGuctmFTq
Need more studies but at minimum probably should see a nutritionist and a physical therapist if losing weight on a GLP1R agonist drug. pubmed.ncbi.nlm.nih.gov/39295512/
Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity https://t.co/h37ZVjxrG1
RT @agingdoc1: Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity https://t.co/wxyKDc2Lsd…
Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity https://t.co/E8UwyyfpTG
Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity. Resistance exercise https://t.co/HZbuN0MIDp
肥満治療にGLP-1RAを使う上で筋肉の減少を最大限に減らすための戦略 適切な栄養管理：十分なタンパク質摂取は、筋肉の維持に不可欠 運動の実施：レジスタンストレーニング 個別化された治療計画：患者の状態や目標に合わせた治療計画を立てる https://t.co/RtfsSVIgEQ
RT @DrRaniKhatib: Users of incretin-mimetics in obesity trials lost ≥10% of muscle mass during the 68 -72 week interventions, approx equiva…
RT @DrRaniKhatib: Users of incretin-mimetics in obesity trials lost ≥10% of muscle mass during the 68 -72 week interventions, approx equiva…
RT @DrRaniKhatib: Users of incretin-mimetics in obesity trials lost ≥10% of muscle mass during the 68 -72 week interventions, approx equiva…
RT @DrRaniKhatib: Users of incretin-mimetics in obesity trials lost ≥10% of muscle mass during the 68 -72 week interventions, approx equiva…
RT @DrRaniKhatib: Users of incretin-mimetics in obesity trials lost ≥10% of muscle mass during the 68 -72 week interventions, approx equiva…
RT @DrRaniKhatib: Users of incretin-mimetics in obesity trials lost ≥10% of muscle mass during the 68 -72 week interventions, approx equiva…
Users of incretin-mimetics in obesity trials lost ≥10% of muscle mass during the 68 -72 week interventions, approx equivalent to 20 yrs of age-related muscle loss. Strategies for minimizing muscle loss during use of IMs drugs for treatment of obesity onlinelibrary.wiley.com/doi/10.1111/...
RT @DrRaniKhatib: Users of incretin-mimetics in obesity trials lost ≥10% of muscle mass during the 68 -72 week interventions, approx equiva…
RT @DrRaniKhatib: Users of incretin-mimetics in obesity trials lost ≥10% of muscle mass during the 68 -72 week interventions, approx equiva…
Users of incretin-mimetics in obesity trials lost ≥10% of muscle mass during the 68 -72 week interventions, approx equivalent to 20 yrs of age-related muscle loss. Strategies for minimizing muscle loss during use of IMs drugs for treatment of obesity https://t.co/dsMrPXq7WE https://t.co/R2ZEwFSUhb
RT @MWeintraubMD: The benefits of incretin-memetic drugs (IMD) are clear
RT @pash22: Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity https://t.co/tfoRuuQqwS via…
Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity https://t.co/tfoRuuQqwS via @heymsfield et al @PharmRJ
RT @MWeintraubMD: The benefits of incretin-memetic drugs (IMD) are clear
RT @MWeintraubMD: The benefits of incretin-memetic drugs (IMD) are clear
RT @MWeintraubMD: The benefits of incretin-memetic drugs (IMD) are clear
RT @MWeintraubMD: The benefits of incretin-memetic drugs (IMD) are clear
RT @MWeintraubMD: The benefits of incretin-memetic drugs (IMD) are clear
RT @MWeintraubMD: The benefits of incretin-memetic drugs (IMD) are clear
RT @MWeintraubMD: The benefits of incretin-memetic drugs (IMD) are clear
RT @MWeintraubMD: The benefits of incretin-memetic drugs (IMD) are clear
RT @MWeintraubMD: The benefits of incretin-memetic drugs (IMD) are clear
The benefits of incretin-memetic drugs (IMD) are clear
RT @sociedadSEEN:
RT @sociedadSEEN:
RT @sociedadSEEN:
RT @sociedadSEEN:
RT @sociedadSEEN:
RT @sociedadSEEN:
RT @sociedadSEEN:
RT @sociedadSEEN:
RT @sociedadSEEN:
RT @sociedadSEEN:
https://t.co/ekrNOGCtOz https://t.co/w23Thpu1xZ
RT @agingdoc1: Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity https://t.co/wxyKDc2Lsd…
Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity https://t.co/wxyKDc2Lsd https://t.co/4BQmfA4aP5
RT @Office_j: 【備忘】 Obes Rev誌に、インクレチン関連薬を用いた肥満治療における筋肉減少抑制を論じたレビュー。同剤による筋肉減少は加齢20年分に相当する可能性にも言及。 https://t.co/rTglujtooH https://t.co/M1IV…
Strategies for minimizing muscle loss during use of incretin‐mimetic drugs for treatment of obesity - Mechanick - Obesity Reviews - Wiley Online Library https://t.co/zLSsDH6pPo
RT @PrimaryCarePAC: Hey! What can we do to avoid lean mass loss with weight loss? Check out this recent paper with me: Strategies for mi…
RT @PrimaryCarePAC: Hey! What can we do to avoid lean mass loss with weight loss? Check out this recent paper with me: Strategies for mi…
RT @PrimaryCarePAC: Hey! What can we do to avoid lean mass loss with weight loss? Check out this recent paper with me: Strategies for mi…
RT @PrimaryCarePAC: Hey! What can we do to avoid lean mass loss with weight loss? Check out this recent paper with me: Strategies for mi…
RT @PrimaryCarePAC: Hey! What can we do to avoid lean mass loss with weight loss? Check out this recent paper with me: Strategies for mi…
RT @PrimaryCarePAC: Hey! What can we do to avoid lean mass loss with weight loss? Check out this recent paper with me: Strategies for mi…
@DrCarlaPrado @imwmhealth @DrZhaopingLi @heymsfield @DrNadolsky Okay, now go read the full study here: https://t.co/fKGEAJpHa1
Hey! What can we do to avoid lean mass loss with weight loss? Check out this recent paper with me: Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity https://t.co/S81wbAw4E6
RT @NeilFlochMD: Strategies for minimizing muscle loss during use of incretin‐mimetic drugs for treatment of obesity - Mechanick - Obesity…
RT @NeilFlochMD: Strategies for minimizing muscle loss during use of incretin‐mimetic drugs for treatment of obesity - Mechanick - Obesity…
RT @NeilFlochMD: Strategies for minimizing muscle loss during use of incretin‐mimetic drugs for treatment of obesity - Mechanick - Obesity…
RT @NeilFlochMD: Strategies for minimizing muscle loss during use of incretin‐mimetic drugs for treatment of obesity - Mechanick - Obesity…
RT @NeilFlochMD: Strategies for minimizing muscle loss during use of incretin‐mimetic drugs for treatment of obesity - Mechanick - Obesity…
Strategies for minimizing muscle loss during use of incretin‐mimetic drugs for treatment of obesity - Mechanick - Obesity Reviews - Wiley Online Library https://t.co/I19Yp8d0Ae
【備忘】 Obes Rev誌に、インクレチン関連薬を用いた肥満治療における筋肉減少抑制を論じたレビュー。同剤による筋肉減少は加齢20年分に相当する可能性にも言及。 https://t.co/rTglujtooH https://t.co/M1IVxmzMoO